Investors in JAZZ Pharmaceuticals plc (JAZZ) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $70.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It co ...

Ms. Pearce brings over 30 years of commercial experience and track record of success across global marketsDUBLIN, July 9, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Samantha Pearce, Senior Vice President (SVP), Europe and International, has been promoted to Chief Commercial Officer (CCO) effective August 1, 2024.Ms. Pearce joined Jazz as SVP, Europe and International, in 2020, and brings more than 30 years of commercial experience in the pharmaceutical industry. Since ...

Jazz Pharmaceuticals (JAZZ) announced that a mid-stage study evaluating the efficacy and safety of its investigational candidate, suvecaltamide (JZP385), in adult patients with essential tremor (ET) did not meet its primary endpoint. Suvecaltamide is a highly selective and state-dependent modulator of T-type calcium channels, which play a role in the brain's control of muscle movement. Per the data readout from the phase IIb study (NCT05122650), treatment with suvecaltamide 30mg failed to achieve statistica ...

deliormanli Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) fell yesterday after the company announced that suvecaltamide failed to meet the primary endpoint in the phase 2b trial in patients with essential tremor. The company is blaming a higher placebo response, but I was not surprised by this failure. As I wrote in my January 2024 article, my expectations were low based on the available data from the previous trial. There are far more important assets and events to focus on - the performance of the comm ...

DUBLIN, June 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET). Suvecaltamide did not achieve statistical significance at 30mg versus placebo on the primary endpoint of change from baseline to week 12 on the Essenti ...

Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors With approximately two years of median follow-up, as of July 28, 2023, median duration of response (DOR) increased by two months from initial analysis to 14.9 months DUBLIN, June 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the firs ...

DUBLIN, May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcare Conference on Thursday, June 6, 2024 Fireside chat at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 Fireside chat at 7:40 a.m. PT / 10:40 a.m. ET / 3:40 p.m. IST Audio webcasts of the presentations will be available via the Inves ...

Target Action (PDUFA) Date set for November 29, 2024 If approved, zanidatamab will be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic biliary tract cancer DUBLIN, May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2 ...

DUBLIN, May 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States. This partnership reinforces Jazz's commitment to supporting the communities in which employees work and live. Life Science Cares is a collective effort to activate the financial and human capital of the life sciences industry across several regions in the U.S. – and partner with nonprofits – t ...

If the market’s dramatic shifts this year leave you discombobulated, you’re not alone. But, despite widespread overvaluation across a range of tech stocks, plenty of cheap blue-chip stocks are ready to offer the portfolio stability we’re all desperately seeking. Amidst the current rally, we’ve seen stocks rise, plummet and rise again, driving investors toward small-caps, tech and growth stocks. While this has been profitable, it might not be the best long-term move. Cheap blue- chip stocks, on the other han ...